CA-RAFTR
Silicon Valley-based higher ed tech company Raftr announced today that it will offer its messaging and notifications platform free of charge through July 1, 2020 to colleges and universities, many of which are facing disruption and dislocation as a result of COVID-19 concerns. Each institution’s network is entirely private, limited to that community’s constituents.
The app facilitates immediate and direct communication between college administrations and their students in a mobile-first platform, enabling instant direct messaging to students’ mobile devices.
“Our partner institutions are facing a rapidly evolving COVID-19 outbreak, forcing unprecedented disruption on campuses and in remote learning environments,” Raftr Founder & CEO Sue Decker says. “The right thing to do is to offer our support. Raftr enables immediate communication between universities and their students, faculty, staff, and even parents, anywhere in the world. Exceptionally fast to implement, the interactive, flexible and coordinated communication platform can stand-alone or supplement email communication.”
Raftr enables group administrators to send custom push notifications directly to students’ and parents’ mobile devices, highlighting important updates about issues related to COVID-19, including online learning, study abroad cancellations or updates, academic information, and more.
Key features and customization options for different campus constituents include:
Administration:
- Public and private chat channels for sharing information, and Q&A in real time.
- Optional automatic posting of existing COVID-19 updates from authenticated sources, including CDC, the WHO, and/or existing university sources.
- Curated organization of all past communications for easy discovery and access.
Faculty:
- Ability to host real-time, virtual discussions and “office hours” in private channels for online courses, easily discoverable by students.
- Creation of an online lecture calendar with days / times of courses and ability to link directly to Zoom, Hangouts, or other online learning platforms.
- Direct and group chat options to stay connected to students one-on-one or in class settings.
- Ability to add links to important teaching materials.
Students:
- Creation of digital communities that mirror those on campus, including classes, student groups, social groups, and volunteer organizations.
- Ability to create unlimited public or private groups to maintain student organization communication and planning.
- Access to group chats, topic channels, direct messaging, photos & videos, polls and more.
Decker says the free use of the platform will be granted through July 1. To be eligible, administrators are asked to submit a request to enable their community and attend a one-hour online training session for any staff members who will be posting updates in the platform. Those staff members will be given access to Raftr ProTools, including the ability to send custom push notifications with important updates.
Online Request Form
Submit a request
Connect on Social
Twitter
LinkedIn
Facebook
About Raftr
Raftr promotes the power of belonging by building dynamic and safe digital communities through an intuitive student-centric communication platform. Each enabled school’s experience will be accessible only by that institution’s students, faculty, staff and parents, creating a private, curated, and trusted network. Raftr’s solutions cover every stage of undergraduate and alumni life, with packages for News & Events, Residence Life, Club & Groups / Academic Departments, and Orientation. The platform is available via mobile applications and website, and primary features include events, messaging, push notifications, polls and more. Additional information is available at https://pro.raftr.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005649/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
